Table 4.
Survival and progression-free survival from diagnosis, and parameters of KD initiation, KD duration during and after protocol treatment, time from KD start and KD end till death (all in months) and KD compliance
| Subject no. | Group no. | Age | Overall survival1 | Dx-KD start | Study RX duration | KD continued after study | KD start-death | KD start-MRI progression | Compliance2 |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 62 | 29.2 | 2.2 | 6 | 20 | 27 | 7.8 | 3 |
| 2 | 1 | 64 | 11 | 1.5 | 6 | 1 | 9.5 | 1.6 | 3 |
| 3 | 1 | 40 | 25.1 | 1.7 | 6 | 13.3 | 23.4 | 3.9 | 3 |
| 53 | 2 | 48 | 19 | 1.5 | 1 | 0 | 17.5 | 7.1 | 0 |
| 6 | 2 | 62 | 38.7 | 32.4 | 5 | 0 | 6.3 | 2.2 | 2 |
| 7 | 2 | 41 | 13.9 | 6.4 | 0.2 | 0 | 7.5 | 0.6 | NA |
| 8 | 2 | 41 | 30.1 | 10.2 | 6 | 0 | 19.9 | 3.8 | 2 |
Only 7 patients who died are included in the survival analysis. Group 1, newly diagnosed GBM, with KD adjunctive treatment to XRT and temozolomide. Group 2, recurrent GBM, with recurrence/progression after XRT, temozolomide, and recurrence/continued progression on bevacizumab. All months are given to the nearest decimal point
1Overall survival = survival from diagnosis
2Compliance is rated on a scale of 0–3: 0 = none, 1 = partial-slight, 2 = partial-substantial, 3 = complete
3Study subject no. 4 was alive at the time of submission and was therefore not included in the survival analysis